Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma
- 13 December 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (4) , 582-594
Abstract
CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies. Significance: Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81871235)
- Natural Science Foundation for Distinguished Young Scholars of Hubei province (2020CFA074)
- China Postdoctoral Science Foundation (2019M662642)
This publication has 51 references indexed in Scilit:
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response MagnitudeThe Journal of Immunology, 2012
- Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid ProfilingCancer Research, 2011
- Accumulation of Natural Killer T Cells in Progressive Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in HumansAnnals of the New York Academy of Sciences, 2009
- Senescence‐associated β‐galactosidase is lysosomal β‐galactosidaseAging Cell, 2006
- Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor loadInternational Journal of Cancer, 2005
- Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cellsOncogene, 2001
- Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cellsOncogene, 2000
- Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescenceOncogene, 1998